Komori
Other Disclosures4890Tsubota Laboratory IncorporatedPharmaceuticals

ROHTO PHARMACEUTICAL CO.,LTD. launches “Rohto V5 Vision Power,” newly formulated with crocetin, which Tsubota Laboratory has researched extensively.

“ROHTO V5 Vision Power,” a Foods with Function Claims product containing crocetin that we have researched, will be launched by ROHTO PHARMACEUTICAL CO.,LTD. Under the contract, we will receive consideration based on the product’s sales performance.

Worth reading
60In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

ROHTO V5 Vision Power
Applicable field (uses covered by this announcement)

Maintaining the ability to focus on distant objects, which declines through everyday use of computers and smartphones and similar devices

Launch date20 October 2026 (scheduled launch date)
Relationship between the counterparty and the company
Tsubota Laboratory Incorporated4890
Relationship with the Company

Crocetin based on our research has been adopted in a product of ROHTO PHARMACEUTICAL CO.,LTD. We have a contract under which we will receive consideration based on the product’s sales performance. ROHTO PHARMACEUTICAL CO.,LTD. will handle the product formulation design and notification as a Foods with Function Claims product, and we were not involved in the formulation design.

CounterpartyROHTO PHARMACEUTICAL CO.,LTD.

Head office: Osaka City; Representative Director and President: Segi Hidetoshi (瀬木英俊). Business description, capital and year established: Not disclosed.

Impact on Business Performance

Under the contract, we will receive consideration based on the sales performance of this product, and we expect it to contribute to our revenue going forward. Amount: Not disclosed.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Consumer Affairs Agency Foods with Function Claims Notification Information Search Database

Announced details
ItemDetails
Names of Products / Services CoveredROHTO V5 Vision Power
CounterpartyROHTO PHARMACEUTICAL CO.,LTD.
Counterparty overviewHead office: Osaka City; Representative Director and President: Segi Hidetoshi (瀬木英俊). Business description, capital and year established: Not disclosed.
Relationship with the CompanyCrocetin based on our research has been adopted in a product of ROHTO PHARMACEUTICAL CO.,LTD. We have a contract under which we will receive consideration based on the product’s sales performance. ROHTO PHARMACEUTICAL CO.,LTD. will handle the product formulation design and notification as a Foods with Function Claims product, and we were not involved in the formulation design.
Launch date20 October 2026 (scheduled launch date)
Applicable areaMaintaining the ability to focus on distant objects, which declines through everyday use of computers and smartphones and similar devices
Impact on Business PerformanceUnder the contract, we will receive consideration based on the sales performance of this product, and we expect it to contribute to our revenue going forward. Amount: Not disclosed.
SourceConsumer Affairs Agency Foods with Function Claims Notification Information Search Database
Items this document does not state (10)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To put the research findings on crocetin into practical use, deliver them to consumers and link them to business value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
ROHTO PHARMACEUTICAL CO.,LTD. launches “Rohto V5 Vision Power,” newly formulated with crocetin, which Tsubota Laboratory has researched extensively. | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori